Harvard Medical School, Boston, Massachusetts; Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Massachusetts.
Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts.
Semin Thorac Cardiovasc Surg. 2019 Summer;31(2):290-299. doi: 10.1053/j.semtcvs.2018.10.010. Epub 2018 Nov 2.
The purpose of this study was to quantify the cost impact of complications of esophagectomy and identify opportunities for reducing costs while optimizing outcomes. Patients undergoing esophagectomy at a single institution between 2002 and 2017 were included. Complications were tabulated from clinical data. Direct hospital costs were determined for all encounters between the day of surgery and postoperative day 90. Risk factors were assessed using logistic regression. The relative incremental cost of complications was assessed using multivariable linear regression. A total of 761 patients were included in this study. 428 patients (56%) experienced at least 1 complication. Factors associated with increased likelihood of complications included age (P < 0.001), female sex (P = 0.005), pack-years (P = 0.006), cerebrovascular disease (P = 0.021), and diabetes (P = 0.052). The most common complications were atrial arrhythmia (18%), transfusion (15%), and atelectasis requiring bronchoscopy (8%). The complications incurring the greatest incremental cost per event were anastomotic complications requiring surgical treatment (200%, P < 0.001) or those treated nonoperatively (96%, P < 0.001), and renal failure (178%, P < 0.001). Pneumonia increased costs by 40% (P < 0.001) and other major pulmonary complications increased costs by 75% (P < 0.001). Though the cost of complications was unaffected by surgical approach (minimally invasive esophagectomy vs open), MIE was associated with decreased cost vis-à-vis a lower complication rate (41% vs 60%, P < 0.001). Complications accounted for 28% of the aggregate 90-day direct hospital cost for all patients. Pulmonary complications accounted for 35% of all complication-attributable costs, while anastomotic complications accounted for 17%. Anastomotic and pulmonary complications after esophagectomy with gastric conduit reconstruction represent high-yield targets for cost reduction and quality improvement.
本研究旨在量化食管癌切除术并发症的成本影响,并确定在优化结果的同时降低成本的机会。研究纳入了 2002 年至 2017 年期间在单一机构接受食管癌切除术的患者。从临床数据中列出并发症。所有手术日至术后第 90 天的就诊均确定直接住院费用。使用逻辑回归评估风险因素。使用多变量线性回归评估并发症的相对增量成本。本研究共纳入 761 例患者。428 例(56%)至少发生 1 种并发症。与并发症发生可能性增加相关的因素包括年龄(P<0.001)、女性(P=0.005)、吸烟指数(P=0.006)、脑血管疾病(P=0.021)和糖尿病(P=0.052)。最常见的并发症是房性心律失常(18%)、输血(15%)和需要支气管镜检查的肺不张(8%)。每例并发症导致增量成本最高的是需要手术治疗的吻合口并发症(200%,P<0.001)或非手术治疗的吻合口并发症(96%,P<0.001),以及肾衰竭(178%,P<0.001)。肺炎使成本增加 40%(P<0.001),其他主要肺部并发症使成本增加 75%(P<0.001)。尽管并发症的成本不受手术方法(微创食管切除术与开放手术)的影响,但 MIE 与较低的并发症发生率相关,从而降低了成本(41%比 60%,P<0.001)。并发症占所有患者 90 天总直接住院费用的 28%。肺部并发症占所有并发症相关费用的 35%,而吻合口并发症占 17%。胃管重建后食管癌切除术的吻合口和肺部并发症是降低成本和提高质量的高收益目标。